Simultaneous in vivo measurements of receptor density and affinity using [11C]flumazenil and positron emission tomography: Comparison of full saturation and steady state methods

The binding of PET radiotracer [(11)C]flumazenil to the GABA(A) receptors is described by the receptor density (B(max)) and binding affinity (K(D)). The estimation of B(max) and K(D) is usually based on Scatchard analysis including at least two PET scans at steady state of various specific activities. Recently, a novel full saturation method to estimate both B(max) and K(D) was proposed, in which a saturating dose of flumazenil is given to cover a wide range of different receptor occupancies within a single scan. The aim of the present study was a direct comparison of steady state and full saturation methods for determining B(max) and K(D) of [(11)C]flumazenil in the same group of male Sprague-Dawley rats. Fourteen rats underwent 3 consecutive [(11)C]flumazenil scans of 30 min duration each. A tracer dose was injected at the start of the first scan. Prior to the second scan the tracer was mixed with 5, 20, 100 or 500 μg unlabelled (cold) flumazenil to cover a wide range of receptor occupancies during the scan. The third scan was performed during a constant intravenous infusion of unlabelled flumazenil, resulting in ~50% GABA(A) receptor occupancy. The first and third scans were part of the steady state method, whilst the second scan was performed according to the full saturation method. For both methods, B(max) and K(D) were then derived by compartmental modelling. Both methods yielded similar B(max) and K(D) estimates. The full saturation method yielded B(max) values of 37 ± 5.8 ng · mL(-1) and K(D) values of 7.6 ± 2.0 ng · mL(-1), whilst the steady state method yielded B(max) values of 33 ± 5.4 ng · mL(-1) and K(D) values of 7.1 ± 0.8 ng · mL(-1). The main advantage of the full saturation method is that B(max) and K(D) can be obtained from a single PET scan.

[1]  Ronald Boellaard,et al.  Population Pharmacokinetic Analysis for Simultaneous Determination of Bmax and KDIn Vivo by Positron Emission Tomography , 2005, Molecular Imaging and Biology.

[2]  Andrew C. Hooker,et al.  Conditional Weighted Residuals (CWRES): A Model Diagnostic for the FOCE Method , 2007, Pharmaceutical Research.

[3]  J. Baron,et al.  Central benzodiazepine receptors in human brain: estimation of regional Bmax and KD values with positron emission tomography. , 1992, European journal of pharmacology.

[4]  M Danhof,et al.  Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of the Electroencephalogram Effects of GABAA Receptor Modulators: In Vitro-in Vivo Correlations , 2003, Journal of Pharmacology and Experimental Therapeutics.

[5]  Wolfgang Löscher,et al.  Antiepileptic drug-resistant rats differ from drug-responsive rats in hippocampal neurodegeneration and GABAA receptor ligand binding in a model of temporal lobe epilepsy , 2006, Neurobiology of Disease.

[6]  Yasuyoshi Watanabe,et al.  Receptor imaging technique with 11C-labeled receptor ligands in living brain slices: its application to time-resolved imaging and saturation analysis of benzodiazepine receptor using [11C]Ro15-1788 , 1996, Neuroscience Research.

[7]  Adriaan A Lammertsma,et al.  Population plasma pharmacokinetics of 11C-flumazenil at tracer concentrations. , 2005, British journal of clinical pharmacology.

[8]  T Revesz,et al.  Central benzodiazepine receptor autoradiography in hippocampal sclerosis , 1997, British journal of pharmacology.

[9]  Bernard Bendriem,et al.  Modeling Analysis of [11C]Flumazenil Kinetics Studied by PET: Application to a Critical Study of the Equilibrium Approaches , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[10]  Kazuhiko Yanai,et al.  In vivo evaluation of P-glycoprotein modulation of 8 PET radioligands used clinically. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  M O Karlsson,et al.  Diagnosing Model Diagnostics , 2007, Clinical pharmacology and therapeutics.

[12]  Sanjiv S. Gambhir,et al.  AMIDE: A Free Software Tool for Multimodality Medical Image Analysis , 2003 .

[13]  M Danhof,et al.  Pharmacokinetic-pharmacodynamic modeling of the electroencephalographic effects of benzodiazepines. Correlation with receptor binding and anticonvulsant activity. , 1991, The Journal of pharmacology and experimental therapeutics.

[14]  Jouke Dijkstra,et al.  Changes in GABAA receptor properties in amygdala kindled animals: In vivo studies using [11C]flumazenil and positron emission tomography , 2009, Epilepsia.

[15]  Lee W. Schruben,et al.  Modeling & Analysis , 2003, NeuroImage.

[16]  Ronald Boellaard,et al.  Performance evaluation of the ECAT HRRT: an LSO-LYSO double layer high resolution, high sensitivity scanner , 2007, Physics in medicine and biology.

[17]  Goonaseelan Pillai,et al.  Non-Linear Mixed Effects Modeling – From Methodology and Software Development to Driving Implementation in Drug Development Science , 2005, Journal of Pharmacokinetics and Pharmacodynamics.

[18]  E N Jonsson,et al.  Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. , 1999, Computer methods and programs in biomedicine.

[19]  Ronald Boellaard,et al.  Impact of attenuation correction strategies on the quantification of High Resolution Research Tomograph PET studies , 2008, Physics in medicine and biology.

[20]  Ronald Boellaard,et al.  HRRT Versus HR+ Human Brain PET Studies: An Interscanner Test–Retest Study , 2009, Journal of Nuclear Medicine.

[21]  Peter Ott,et al.  Blood—Brain Barrier Transport and Protein Binding of Flumazenil and Iomazenil in the Rat: Implications for Neuroreceptor Studies , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[22]  Justin J. Wilkins,et al.  NONMEMory: A run management tool for NONMEM , 2005, Comput. Methods Programs Biomed..

[23]  J. S. Duncan,et al.  Benzodiazepine Receptor Quantification in vivo in Humans Using [11C]Flumazenil and PET: Application of the Steady-State Principle , 1995, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[24]  E. Korpi,et al.  Regulation of GABAA Receptor Subunit Expression by Pharmacological Agents , 2010, Pharmacological Reviews.

[25]  R. P. Maguire,et al.  Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[26]  D Comar,et al.  Synthesis of ethyl 8-fluoro-5,6-dihydro-5-[11C]methyl-6-oxo-4H-imidazo [1,5-a] [1,4]benzodiazepine-3-carboxylate (RO 15.1788-11C): a specific radioligand for the in vivo study of central benzodiazepine receptors by positron emission tomography. , 1984, The International journal of applied radiation and isotopes.

[27]  J Delforge,et al.  Quantitation of benzodiazepine receptors in human brain using the partial saturation method. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.